Resources
23 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.
Posted 8/17/2022 (updated 3/27/2024)
The National Advisory Committee on Rural Health and Human Services recently published a policy brief on behavioral health and primary care integration in rural health facilities.
Posted 4/20/2022 (updated 3/27/2024)
This updated (March 2020) TIP is intended to provide addiction counselors and other providers, supervisors, and administrators with the latest science in the screening, assessment, diagnosis, and management of co-occurring disorders (CODs).
Posted 3/24/2022 (updated 3/27/2024)
If you received specific disposal instructions from your healthcare provider (e.g., doctor, pharmacist) for your unused or expired medicine, you should follow those instructions to dispose of your medicine. The best disposal option is to find a drug take back location, which may be found in retail, hospital, or clinic pharmacies; and/or law enforcement facilities.
Posted 3/21/2022 (updated 3/27/2024)
NIDAMED’s mission is to develop science-based resources for health professionals and those in training about screening, addressing, and treating addiction.
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 6/2/2021 (updated 4/10/2024)
This webinar provided a review of basic principles of integrated behavioral health and an update on recent outcomes and implementation research.